Others Urological ConditionsArchives
Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad study
Others Urological Conditions 1 min.
Others Urological Conditions
1 min.
Published on 31/07/2026 |
Original article (Full-text)
| Amrane, Karim et al. | Cancer Immunology, Immunotherapy. Volume 75(8).
Histologic variants (HV) of urothelial carcinoma (UC-V) and non-urothelial carcinomas (NUC) of the bladder and urinary tract are aggressive malignancies with poor prognosis and limited response to platinum-based chemotherapy. Despite their biological particularities and distinct immune microenvironments,...
Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS)
Others Urological Conditions 1 min.
Others Urological Conditions
1 min.
Published on 24/07/2026 |
Original article (Full-text)
| Zschäbitz, Stefanie et al. | Cancer Immunology, Immunotherapy. Volume 75(7).
Enfortumab vedotin plus pembrolizumab (EVP) is the standard first-line treatment for metastatic or locally advanced urothelial carcinoma (m/laUC). Real-world patients frequently present with unfavorable clinical characteristics, raising uncertainty about whether outcomes mirror those of the pivotal EV-302/KEYNOTE-A39...
